The use of several promising drugs as treatments for autoimmune and inflammatory diseases has long been limited due to their toxic side effects. Wang et al. demonstrate how these barriers could be overcome with a novel antibody-drug conjugate.
How can we do even more to help researchers? That’s a question we ask a lot here at Vector Laboratories, and this June it led us to launch a blog. Since then, it’s been our honor to bring you stories about innovative scientists and share insights to help you advance your research. Here are a few of our most popular posts from 2021, and we’re looking forward to many more tips and stories in 2022!
Since it was first described in 1906 by Alois Alzheimer, physicians and scientists have been searching for clues to the debilitating neurological condition Alzheimer’s disease (AD). To diagnose and treat the disease at its earliest stages, researchers are searching for additional biomarkers that can help guide our understanding of the disease.
With applications ranging from drug targeting to genome sequencing, bioconjugation provides tools for more effective imaging and drug discovery methods. Join us as we explore the possibilities in this article.
In this publication highlight, we review the use of LIBRA-seq to characterize monoclonal antibodies from a recovered SARS-CoV donor, expanding our understanding of cross-reactive antibodies for coronavirus.
Bioconjugation offers a way to chemically link two molecules to form a single hybrid, where at least one of the molecules in the partnership is a biomolecule. The resulting product retains the activity of each component, yet also gains novel functionality that is not possible with either molecule alone. In a recent webinar, Dr. Craig Pow, Director of Technical Services at Vector Laboratories provided an introduction to bioconjugation and its applications, as well as key factors to success.
